(Q33891020)

29 July 2017

title

Validating new tuberculosis computational models with public whole cell screening aerobic activity datasets (English)

1 reference

29 July 2017

0 references

1

1 reference

29 July 2017

2

Joel S Freundlich

1 reference

29 July 2017

publication date

10 March 2011

1 reference

29 July 2017

published in

Pharmaceutical Research

1 reference

29 July 2017

volume

28

1 reference

29 July 2017

issue

8

1 reference

29 July 2017

page(s)

1859-1869

1 reference

Rising standards for tuberculosis drug development

29 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS11095-011-0413-X

The magic bullets and tuberculosis drug targets.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-011-0413-X

New small-molecule synthetic antimycobacterials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-011-0413-X

Virtual screening: an endless staircase?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-011-0413-X

Global Bayesian models for the prioritization of antitubercular agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-011-0413-X

Discovery of novel nitrobenzothiazole inhibitors for Mycobacterium tuberculosis ATP phosphoribosyl transferase (HisG) through virtual screening

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-011-0413-X

Is there a difference between leads and drugs? A historical perspective

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-011-0413-X

Computational approaches that predict metabolic intermediate complex formation with CYP3A4 (+b5).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-011-0413-X

High-throughput screening for inhibitors of Mycobacterium tuberculosis H37Rv

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-011-0413-X

Analysis and hit filtering of a very large library of compounds screened against Mycobacterium tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-011-0413-X

Meta-analysis of molecular property patterns and filtering of public datasets of antimalarial “hits” and drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-011-0413-X

When pharmaceutical companies publish large datasets: an abundance of riches or fool's gold?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-011-0413-X

ALARM NMR: a rapid and robust experimental method to detect reactive false positives in biochemical screens

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-011-0413-X

Toxicological evaluation of thiol-reactive compounds identified using a la assay to detect reactive molecules by nuclear magnetic resonance

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-011-0413-X

Enhancement of chemical rules for predicting compound reactivity towards protein thiol groups

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-011-0413-X

New anti-tuberculosis agents amongst known drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-011-0413-X

Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-011-0413-X

Integrated in silico-in vitro strategy for addressing cytochrome P450 3A4 time-dependent inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-011-0413-X

Prediction of Hydrophobic (Lipophilic) Properties of Small Organic Molecules Using Fragmental Methods: An Analysis of ALOGP and CLOGP Methods

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-011-0413-X

Identification and evaluation of molecular properties related to preclinical optimization and clinical fate

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-011-0413-X

A small-molecule nitroimidazopyran drug candidate for the treatment of tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-011-0413-X

OPC-67683, a nitro-dihydro-imidazooxazole derivative with promising action against tuberculosis in vitro and in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-011-0413-X

Recognizing molecules with drug-like properties

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-011-0413-X

A virtual screening approach for thymidine monophosphate kinase inhibitors as antitubercular agents based on docking and pharmacophore models

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-011-0413-X

Antituberculosis activity of the molecular libraries screening center network library

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-011-0413-X

Strategic Pooling of Compounds for High-Throughput Screening

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-011-0413-X

A collaborative database and computational models for tuberculosis drug discovery

21 January 2018

1 reference

12 December 2020

Predicting cytotoxicity from heterogeneous data sources with Bayesian learning.

1 reference

12 December 2020

Computational databases, pathway and cheminformatics tools for tuberculosis drug discovery

1 reference

12 December 2020

Essential metabolites of Mycobacterium tuberculosis and their mimics

1 reference

12 December 2020

Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings

1 reference

12 December 2020

10.1007/S11095-011-0413-X

Identifiers

DOI

1 reference

29 July 2017

1 reference